---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000052"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:18:09.977582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track

## Summary
- Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.
- Cash $693.5M at March 31; expects year-end 2025 cash $535-585M, funding operations into 2028.
- Nancy Valente, EVP & CDO, to resign June 6, 2025, remain as senior advisor; clinical leaders report to CEO.
- XmAb942 interim Phase 1 shows half-life >71 days, supports Q12W maintenance dosing; Phase 2b XENITH-UC starts H2 2025.
- Earned $12.5M milestone from Incyte for tafasitamab sBLA acceptance, $2.0M from Vir for tobevibart Phase 3 start.

## SEC filing metadata
- accession: 0001326732-25-000052
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/0001326732-25-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/xncr-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000052
- JSON: https://secwatch.observer/filing/0001326732-25-000052.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000052.txt

## Key facts
- Executive change
  Nancy Valente resigned as Executive Vice President and Chief Development Officer at Xencor Inc.
  - Action: resigned
  - Role: Executive Vice President and Chief Development Officer
  source text: On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/0001326732-25-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.